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ABSTRACT 
Background and aims: Mixed hepatocellular-cholangiocarcinoma (HCC-CCA) is a rare 
and poorly understood type of primary liver cancer. We aimed to perform a 
comprehensive molecular characterization of this malignancy.  
Methods: We performed gene expression profiling, DNA copy number detection, and 
exome sequencing using formalin-fixed samples from 18 patients with mixed HCC-CCA 
encompassing the whole histological spectrum of the disease. Comparative genomic 
analysis was performed with independent datasets of HCC (n=164) and iCCA (n=149). 
Results: Integrative genomic analysis of HCC-CCAs revealed that cholangiolocellular 
carcinoma (CLC) represents a distinct biliary-derived entity compared with the stem-cell 
and classical types. CLC tumors were NCAM positive (6/6 vs 1/12, P<0.001), 
chromosomally stable (mean chromosomal aberrations 5.7 vs 14.1, P=0.008), showed 
significant upregulation of TGF-beta signaling and enrichment for inflammation-related 
and immune response signatures (P<0.001). Stem-cell tumors were characterized by 
SALL4 positivity (6/8 vs 0/10, P<0.001), enrichment of progenitor-like signatures, 
activation of specific oncogenic pathways (i.e. MYC and IGF), and signatures related to 
poor clinical outcome. Regarding classical type, a significant correlation in the copy 
number aberrations of the iCCA and HCC components suggested a clonal origin. Exome 
sequencing revealed an average of 63 non-synonymous mutations per tumor (mean driver 
mutations:2). Among those, TP53 was the most frequently mutated gene (6/21, 29%) in 
HCC-CCAs.  
Conclusions: Mixed HCC-CCA represents a heterogeneous group of tumors, with stem-
cell type characterized by features of poor prognosis and classical type with common 
lineage for HCC and iCCA components. CLC stands alone as a distinct biliary-derived 
entity associated with chromosomal stability and TGF-beta signaling.  
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LAY SUMMARY 
The molecular characterization of mixed hepatocellular cholangiocarcinoma (HCC-CCA) 
defined that cholangiolocellular carcinoma (CLC) is a distinct molecular entity with biliary-
derived origin and no traits of HCC. On the other hand, within the mixed HCC-CCA, the 
stem-cell type shared aggressive phenotype and poor outcome whereas the classic type 
shows a common cell lineage for both the HCC and the iCCA component. These data 
supports re-defining the pathological classification of mixed HCC-CCA in light of the novel 
molecular data provided.  
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INTRODUCTION 
Liver cancer is the second leading cause of cancer-related deaths, with more than 
850,000 new cases annually worldwide [1]. Mixed hepatocellular-cholangiocarcinoma 
(HCC-CCA) is a rare type of primary liver cancer accounting for less than 1% of all primary 
liver malignancies [2,3]. Diagnosis is based on histological examination and requires 
unequivocal presence of both hepatocellular carcinoma (HCC) and intrahepatic 
cholangiocarcinoma (iCCA) elements intimately admixed [2]. Due to its low incidence and 
the lack of an established consensual pathological diagnosis, the demographic features 
and clinical behavior of these tumors remain ill-defined. Roughly, the age, sex specific 
incidence and geographical distribution are similar to those for HCC [2,4,5]. Median 
overall survival rates of HCC-CCA are similar to iCCA [3,6–8]. To date, clinical practice 
guidelines do not include a specific treatment recommendation for HCC-CCA and surgical 
resection, when feasible, remains the standard of practice.  
Histologically, mixed HCC-CCA is a heterogeneous group of primary liver tumors. 
According to the 2010 World Health Organization (WHO) classification [2], they are 
divided in two main categories: the classical type and the stem-cell features type. The 
classical type is characterized by areas of typical HCC and iCCA with an intermediate 
transition which holds mixed features of both entities. The category of stem-cell features is 
further subdivided into typical, intermediate and cholangiolocellular carcinoma (CLC). 
Subtypes with stem-cell features are composed of tumor cells with intermediate 
histological features between hepatocytes and cholangiocytes. In addition, recent studies 
have suggested the presence of distinct properties for each subtype of HCC-CCA with 
stem-cell features given their association with different clinicopathological factors [9,10].  
Unlike HCC or iCCA, there is no genome-wide characterization of mixed HCC-CCA 
tumors. Indeed, it is unclear whether histologic subtypes have a well-defined correlate at 
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the molecular level. Gene expression profiling on a small series of HCC-CCA samples 
suggested that HCC-CCA might share common characteristics with poorly differentiated 
HCC and iCCA with stem-cell traits [11–15]. Furthermore, WNT/beta-catenin and TGF-β 
signaling were reported to be significantly activated in mixed HCC-CCA when compared 
to progenitor-like HCC[13]. Mutational analysis has suggested common recurrent driver 
mutations in HCC and HCC-CCA in comparison to iCCA, such as larger frequency of 
TERT promoter mutations and a lower frequency of KRAS and IDH1/2 mutations [14]. On 
the other hand, genome wide allelotyping analyses of classical HCC-CCA suggested a 
closer genomic proximately to iCCA than to HCC [16].  
Herein, we provide a comprehensive molecular characterization of mixed HCC-CCA 
including histological characterization, whole-genome expression profiling, single-
nucleotide polymorphism (SNP) array, and whole-exome sequencing (WES). Integrated 
analysis to evaluate the genomic overlap with a large independent set of HCC and iCCA 
samples was also performed. Overall, integrative genomic analysis indicates that CLC is a 
distinct entity with a biliary molecular profile, low chromosomal instability, and enrichment 
of TGF-β and immune-related signaling. The other mixed tumors can be molecularly 
distinguished in two main subclasses: the stem-cell subclass characterized by the 
presence of the early progenitor marker (SALL4) and signatures of more aggressive 
phenotype, and the classical subclass, constituted by components of both HCC and iCCA 
with a clonal origin. Thus, we propose a molecular classification that encompasses two 
groups within the mixed HCC-CCA tumors (stem-cell and classical). In addition, our data 
suggest that CLC stands alone as an independent biliary-derived entity not sharing any 
molecular traits of HCC. 
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MATERIAL & METHODS 
Human samples and nucleic acid extraction 
For the purpose of this study, we evaluated 4728 consecutive patients who underwent 
surgery for primary liver cancer between 1994 and 2013 at the Icahn School of Medicine 
at Mount Sinai [HCC (4307, 91%), iCCA (360, 7.7%), and mixed HCC-CCA (61, 1.3%)], 
following local Institutional Review Board (IRB) approval. Among the 61 mixed HCC-CCA 
cases, 43 cases were excluded due to several reasons: a) pre-treated with locoregional 
therapies (such as transarterial chemoembolization, TACE), b) lack of sample availability 
or c) low tumor cell viability. The diagnosis of mixed HCC-CCA was confirmed by two 
expert hepato-pathologists (MIF and ST). A final set of 18 patients with available fixed 
paraffin-embedded (FFPE) samples and clinical data were selected and classified 
according to the latest WHO classification [2], as classical (n=4) or with stem-cell features 
(n=14). The stem-cell features subgroup included Typical (n=2), Intermediate (n=6), and 
CLC (n=6). For the purpose of molecular profiling in the case of the classical mixed 
tumors, nucleic acids were extracted separately from the HCC-like and CCA-like 
components (4 patients, 8 tumor samples total). Table 1 summarizes the main clinico-
pathological features of the 18 patients included in the study. For the purpose of 
integrative genomic analysis, molecular data previously reported by our group on HCC 
(n=164) and iCCA (n=149) was used [17,18]. In addition, for the identification of driver 
mutations in stem-cell features subtype, fresh frozen optimal cutting temperature 
compound (FF-OCT) embedded tumor tissues and corresponding normal tissue (n=6 
pairs including 3 overlapping cases with above) were provided by the Mount Sinai 
Institutional Biorepository after IRB committee approval. For detailed description of nucleic 
acid extraction see supplementary Material and Methods section. 
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Immunohistochemistry, Whole-genome gene expression profiling, Genome-wide 
analysis of DNA copy number alteration, Whole-exome sequencing, and Statistical 
analyses 
See Supplementary Materials and Methods section. 
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RESULTS 
CLC, stem-cell and classical types are distinct entities. 
In order to understand if the different histological subtypes of mixed HCC-CCA represent 
distinct subgroups of the disease, we performed gene expression-based unsupervised 
clustering. The unsupervised clustering analysis (Figure 1, Supplementary Figure 1) 
revealed three distinct clustered groups: 1) CLC tumors in cluster C, (P=0.0013), 2) stem-
cell feature tumors in cluster D (P=0.0062), 3) Classical tumors depending on its 
components (HCC-component in clusters A and B, P=0.024). In addition, the fact that the 
iCCA-like components of the classical subtype co-clustered with either stem-cell feature 
tumors or CLC suggest the presence of common molecular traits among these (Figure 
1A). Differential molecular profile of CLC with respect to other stem-cell feature tumors 
was further confirmed by integrative genomic analysis with an independent set of HCC 
(n=164) and iCCA (n=149) samples (Figure 2). CLC tumors significantly co-clustered 
together suggesting high genomic similarity among them in comparison to other primary 
liver tumors (P<0.001). Significant genomic proximity was also observed for stem-cell 
HCC-CCA (P<0.001). Moreover, CLC tumors co-clustered with iCCA from the proliferation 
class, whereas the stem-cell mixed tumors co-clustered with HCC with progenitor-like 
traits (Figure 2, P<0.001). Subsequent analysis of cell lineage with specific marker genes 
further corroborated the observation that CLC may represent a separate entity, as 
indicated by the expression of a biliary phenotype with significant up-regulation of biliary-
specific genes (e.g. KRT7, KRT19, ITGB4) and down-regulation of hepatocyte-related 
genes (e.g. ADH1A, ALB, APOB, HNF1A)[19] (Figure 1). These findings were in 
concordance with the immunostaining profile (Figure 1B and Figure 3), which defined 
CLC tumors as negative for the hepatocyte marker HepPar1 (0/6 in CLC vs 10/12 in 
others, P=0.015, Supplementary table 1), but positive for biliary markers (CK7, CK19) 
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and more specifically the progenitor-like marker NCAM (6/6 in CLC vs 1/12 in others, 
P<0.0001, Supplementary table 1).  
The stem-cell molecular subclass was characterized by the expression of both hepatocyte 
and biliary markers (Figure 1B and Figure 3), and the early progenitor cell marker SALL4 
(6/8 vs 0/10 in rest of mixed tumors, P=0.0004, Supplementary Table 1). On the other 
end of the spectrum, the HCC-like and iCCA-like components of the classical subtype 
showed a biphenotypic profile with simultaneous expression of hepatocytic and biliary 
markers (Figure 1B) despite their distinct histological features (Figure 3). Comparison of 
gene expression levels and immunostaining grading scores showed significant correlation 
for all markers used (Supplementary Figure 2). 
The different genomic profile of CLC tumors was further confirmed by the DNA copy 
number variation (CNV) analysis which revealed significantly higher chromosomal stability 
in CLC compared to the non-CLC tumors (5.7 mean alterations in CLC vs 14.1 for others, 
P=0.008, Figure 4). In contrast, classical and stem-cell subclasses presented frequent 
broad chromosomal aberrations, recapitulating those previously reported in both HCC and 
iCCA, including gains of 1q, and 8q, and losses of 4q, 8p, 9q, 16q and 17p (Figure 4). 
High-level amplifications of 11q13, harboring the oncogenes CCND1 and FGF19, were 
detected in 3 cases of mixed HCC-CCA (Supplementary Table 2). Thus, the above 
findings support that mixed HCC-CCA tumors can be classified into 2 distinct molecular 
subclasses (stem-cell and classical). CLC tumors can be defined as a separate entity with 
biliary phenotype and no traits of HCC. We, then, further characterized the molecular traits 
of each of these tumor subtypes. 
CLC subclass: characterized by TGF-β signaling and immune-related response 
signaling 
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When evaluating previously reported prognostic gene signatures in liver cancer, CLC 
showed a significant enrichment of S1 subclass [20] characterized by higher TGF-β 
activation, and Late TGF-β induced signature [21] (Figure 5A, Supplementary Table 3). 
Furthermore, unsupervised hierarchical clustering with independent set of iCCA and HCC 
samples, suggested a shared molecular profile of CLC and progenitor-like iCCA 
tumors(Figure 2, P<0.001). On the other hand, gene set enrichment analysis (GSEA) of 
canonical and hallmark oncogenic pathways showed that the CLC subclass was 
significantly enriched with TGF-β signaling, epithelial to mesenchymal transition (EMT), 
inflammation and immune response related signaling (i.e. TNF-α, INF-ɣ, IL2/STAT5, 
IL6/STAT3, T cell response) (Supplementary Table 4). Notably, significant enrichment of 
immune cells [22] including T cells (i.e. effector memory, CD8+ PD1 high), cytotoxic 
lymphocytes, T cell helper 1 (Th1), natural killer (NK) and neutrophils was also detected in 
CLC (Figure 5A-middle panel, P<0.05). In addition, specific chemokines (e.g. CXCL12, 
CCL2, CCL21) and several cytokine receptors (i.e. CXCR4, IL8RB, IL10RA, IL17RC) were 
also identified to be significantly up-regulated in CLC (Supplementary Figure 3, 
Supplementary Figure 4). Furthermore, the Ingenuity Pathway Analysis (IPA) of the top 
deregulated genes in CLC (Supplementary Table 5), predicted TGF-β as the major 
activated upstream effector molecule in these tumors (Supplementary Figure 5A, z-
score>2, p<0.0001). Specifically, the ligand TGFB2 was found to be significantly up-
regulated among the different TGF-β superfamily of ligands (Supplementary Figure 3). 
Other significantly deregulated candidate upstream effectors and top bio-functions in CLC 
included activation of TP53 (Supplementary Figure 5A), and DNA damage response 
checkpoint regulation and Ataxia telangiectasia mutated (ATM) signaling (Supplementary 
Figure 5B), respectively. Overall, TGF-β and pro-inflammatory response related signaling 
pathways were found to be specifically up-regulated in CLC tumors.  
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Stem-cell subclass: associated with progenitor-like phenotype and proliferative 
signaling pathways 
We next sought to assess dominant genomic traits in the stem-cell subclass. GSEA of the 
SALL4 positive stem-cell tumors showed enrichment of progenitor-like liver cancer 
subtypes (i.e Stem cell [12], CK19 [17], EpCAM [23]) and more aggressive HCC —
including HCC Proliferation subclass [24], cell-cycle deregulated G3 subclass [25], poor 
survival cluster A [26], and S2 subclass [20]— together with activation of IGF1R [27] and 
NOTCH [28] signaling (Figure 5A, Supplementary Table 3). Consistently, MYC, mTORC 
and NOTCH signaling were identified as the main canonical pathways associated with 
stem cell subclass (Supplementary Table 6). IGF2 signaling was further confirmed as 
one of the main deregulated signaling pathway networks in these tumors (Figure 5C, 
Supplementary Table 7). Another core node up-regulated in stem cell subclass included 
genes implicated in the hepatic specification of liver progenitor cells (i.e. PROX1, HNF1B, 
FOXA1, FOXA3), suggesting a more hepatocyte committed lineage in contrast to the 
biliary phenotype observed in CLC. In addition, consistent with SALL4 expression, the 
pluripotent embryonic related OCT4 signaling was found as one of the top activated 
canonical pathways (Supplementary Figure 6). On the other hand, in regards to CNV 
profiling (Figure 4), the most frequent chromosomal alterations reported in HCC showed 
an enrichment trend in stem-cell subclass, including 1q gains (6/8 vs 2/10), 8q gains (5/8 
vs 1/10), 1p losses (4/8 vs 1/10), and 4q losses (6/8 vs 2/10). Altogether, these data 
suggest that the stem-cell subclass shares common molecular features with more 
aggressive and progenitor-like HCCs.  
Classical subclass: HCC and iCCA components are derived from the same clone  
The classical subclass showed enrichment of the poor prognosis iCCA subclass [29] and 
the chromosome 7 polysomy HCC subclass [24]. By performing separate analysis of the 
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classical iCCA and HCC components, we found enrichment of several gene sets in the 
iCCA component whereas none reached our pre-specified statistical threshold in the HCC 
component (Figure 5A, Supplementary Table 3). Moreover, the classical iCCA 
component seemed to have an intermediate molecular profile to stem-cell and CLC 
subclasses, as it showed association with liver derived gene signatures enriched in either 
stem-cell (i.e. HCC Proliferation, G3, S2, cluster A, CK19, IGF1R) or CLC (i.e. Late TGF-β 
induced signature). GSEA of canonical signaling pathways in the iCCA component 
(Supplementary Table 8) and HCC component (Supplementary Table 9) of the classical 
tumors further suggested a more aggressive phenotype for the iCCA component. 
Pathways enriched in the iCCA component included pro-mitotic DNA replication related 
signaling, proliferative signals such as MYC and mTOR, and pro-inflammatory pathways 
such as INF-ɣ and downstream IL2/STAT5 signaling (Supplementary Table 8). These 
data indicate that the iCCA component of the classical subclass may have a more 
aggressive molecular profile within classical mixed tumors.  
Clonality analysis based on CNV profiling of the HCC-like and iCCA-like components of 
the classical HCC-CCA showed a significant correlation and remarkable similarity (mean 
51%, P<0.001) between both components in 3 out of 4 cases (Supplementary Figure 7 
and 8, Supplementary Table 10). Specifically, focal chromosomal aberrations harboring 
known driver genes (i.e. 11q13 gain and 9p21 deletion), were identified in both 
components in 1 classical subclass case (Supplementary Table 2, Supplementary 
Figure 8). These findings suggest that the HCC and iCCA components of the classic 
subtype may share a common cell of origin that later undergoes clonal divergent 
expansion. 
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Landscape of mutations in mixed HCC-CCA 
Next, we evaluated the mutational landscape of mixed HCC-CCA tumors (4 CLC and 2 
stem-cell, including 3 overlapping cases with above analysis) using exome sequencing. 
Somatic substitutions were predominantly G>A and C>T transitions in both CLC and stem 
cell tumors (Supplementary Figure 9A), as previously reported in iCCA [30,31], HCC 
[32,33] and other cancers [34]. Globally, an average of 63 non-synonymous mutations 
(range 10-129) and 3 small insertions and deletions (indels, range: 1-5, Supplementary 
Table 11) were identified per mixed HCC-CCA tumor (Supplementary Figure 9B). Non-
synonymous mutations included 93% missense (average 59 per tumor, range: 9-115) and 
7% nonsense (average 4 per tumor, range: 1-14,) mutations. Overall, both CLC and stem-
cell subclasses presented similar percentage of missense, silent, and nonsense mutations 
(Figure 6A). Among the non-synonymous mutations, 10 affected known cancer driver 
genes [35,36] (average of 2 driver mutations per tumor), which were confirmed by 
independent PCR and sequencing in each tumor (Figure 6B, Supplementary table 12). 
We further explored the incidence of hot-spot mutations identified by exome sequencing in 
known oncogenic drivers (BRAF, DNMT3A, IDH1) together with recurrent mutations 
reported in HCC (TERT promoter, CTNNB1, TP53) and iCCA (KRAS, FGFR2-BICC1, 
FGFR2-PPHLN1, IDH2) in the remaining FFPE samples. TP53 mutations emerged as the 
most frequent alteration (6/21, 29%), regardless of the subclass (Figure 6C). The 
mutational profile of CLC included TP53 and IDH1, while the stem-cell subclass (i.e. TERT 
promoter, TP53, AXIN1, BRAF, FGFR2-BICC1) seemed to recapitulate those 
characteristic of both HCC and iCCA (Figure 6B and 6C). Interestingly, the most frequent 
HCC driver mutation, TERT promoter mutation, co-occurred with TP53 mutation in 2 
cases (1 classical case and 1 stem-cell SALL4 negative case). The co-occurrence of 
TERT promoter and TP53 mutations (Figure 6C), in both the HCC and iCCA component 
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of the classical subclass case further supported the model of single cell of origin 
suggested by CNV profiling. Other screened mutations such as CTNNB1, KRAS, FGFR2-
PPHLN1 and IDH2 were absent in our cohort. In summary, mutational profiling of mixed 
HCC-CCA revealed common drivers in typical HCC and iCCA tumors. However, the CLC 
subclass seems to have a distinct mutational profile in comparison to stem-cell subclass. 
External validation confirms CLC as a distinct entity from stem-cell HCC-CCA  
We validate the molecular subclasses in a publicly available dataset including 20 HCC-
CCAs described with CLC features [13]. The CLC main molecular characteristics, such as 
biliary committed phenotype and activation of TGF-beta and immune-response signaling, 
were successfully reproduced. (Supplementary Figure 10A). In addition, a CLC-derived 
156-gene signature (Supplementary Table 13) was significantly enriched in ~60% 
(11/20) of these CLC tumors. Subclass mapping approach further reinforced the notion 
that CLC tumors have a sole biliary-like phenotype, with no traits of HCC [37] 
(Supplementary Figure 10B). Moreover, stem-cell HCC-CCAs shared molecular traits of 
HCC but not of CLC tumors (Supplementary Figure 10B) suggesting a hepatocyte 
lineage. These results confirm that CLC and stem-cell mixed tumors represent distinct 
molecular entities. 
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DISCUSSION 
Mixed HCC-CCAs are a heterogeneous group of primary liver cancers. The current 
histological classification describes two main subtypes, classical and with stem-cell 
features. Our study provides molecular evidence confirming a biphenotypical fingerprint 
for stem-cell and classical types, while defining CLC as a separate biliary-derived entity 
with no genomic features of HCC.  We were able to characterize these differences based 
on integrated genomic analysis of gene expression, DNA copy number alteration, 
signaling pathway deregulation and mutational profiling (Figure 7).  
CLC was characterized by chromosomal stability, up-regulation of TGF-beta signaling, 
prominent enrichment in immune-related pathways and defined biliary features. 
Histologically, CLC were characterized by being strongly embedded in fibrous stroma and 
by presenting positive NCAM immune-staining, as previously described [5,11,38,39]. 
Characteristically, TGF-β signaling was activated in CLC tumors as opposed to other 
mixed HCC-CCA. TGF-β is a pleiotropic cascade with different functions depending on the 
cellular context. It exerts pro-tumorigenic effects by enhancing tumor growth and invasion 
through the induction of EMT, activation of myofibroblasts and collagen deposition [40]. 
TGF-β has also been associated with the transformation of hepatic progenitor cells 
(HPCs) into tumor initiating cells [41] and biliary differentiation during early development 
[42]. From the signaling stand point, CLC tumors also showed up-regulation of EMT-
related markers, down-regulation of hepatocyte specific gene markers and enrichment in 
immune cells (T cells, cytotoxic lymphocytes, Th1, NK) and immune-response related 
gene signatures. Particularly, the CXCL12-CXCR4 axis, which has been described to be 
instrumental for the chemoattraction of myeloid and lymphoid cells in to the tumor [43], 
was also shown to be significantly up-regulated in CLC. All these findings -coordinated 
Th1 cell and cytotoxic immune infiltration- are consistent with those reported in other 
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tumor types [44–46]. It is intriguing to understand how activation of TGF-β signaling, which 
is a known immune-suppressor, coexists with activation of T cells in the same tumor, a 
finding that requires further studies. In our view, all these specific molecular traits support 
the concept that CLC should stand alone as a molecularly differentiated subtype of 
intrahepatic biliary carcinomas.  
Tumors belonging to the stem-cell subclass share completely distinct molecular traits. 
First, they showed enrichment for signatures defining activation of proliferative signals 
such as MYC, IGF2, mTOR and NOTCH and HCC poor prognosis. Histologically, they 
were characterized by the presence of SALL4 – an early progenitor-like marker- in 75% 
(6/8) of cases compared to none of other mixed subclasses. Of note, re-expression of the 
oncofetal SALL4 transcription factor has also been described in a subset of HCCs with 
progenitor features and poor prognosis [47]. 
The classical subtype represents a completely distinct entity, since it shares features from 
both typical HCC and iCCA. Our findings support a single cell of origin model for these 
tumors based on similarities in CNV aberrations in HCC and iCCA components in 3 out of 
4 paired cases. These results are aligned with previous findings based on LOH analysis 
where 70% (8 out of 11) of the cases studied showed significant similarities [48]. 
Moreover, the presence of a characteristic transition area between the HCC and iCCA 
components with biphenotypic features [2], further supports the model of a single clonal 
process in which genetic divergence within the tumor parallels the histological diversity. 
From the molecular stand point, each component retained genomic and biomarker traits 
resembling either HCC or iCCA. Similarly, mutational profiling data showed common 
oncogenic driver mutations characteristic of either HCC or iCCA in classical HCC-CCA 
subclass. Finally, we did not identify WNT/β-catenin signaling activation or presence of 
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CTNNB1 mutations in our classical HCC-CCA samples, in agreement with previous 
studies [13,16]. 
After thoroughly exploring all genomic results, we can speculate on the diverse cellular 
lineage of this heterogeneous group of tumors (Supplementary Figure 11). Certainly, our 
results support the possible existence of multiple cells of origin [49]. Mixed HCC-CCA may 
share a common ancestor, the HPCs, but also might derive from more mature progenitor 
cells. Our gene expression profiling data suggested a biliary committed precursor in the 
CLC cases and a biphenotypic progenitor-like precursor in the stem-cell and classical 
subtypes. First, CLC characteristically express NCAM, and has a loss of hepatocyte 
markers only retaining cholangiocyte markers, both features suggesting a more mature 
biliary progenitor ancestor. In addition, IDH1 mutation, a known inhibitor of hepatocyte 
differentiation and gatekeeper for iCCA generation [19], was only detected in CLC. 
Conversely, the stem cell subclass might derive directly from HPCs, or from 
transdifferentiation of more mature ancestors. Specifically, those tumors were enriched 
with stem-cell signatures and SALL4 positive staining and, thus are the logical candidates 
to derive from HPC lineage. Finally, the classical subtype retained markers of both HCC 
and iCCA, and since it seems to have a clonal origin, the cells of origin should be mature 
enough to have lost early progenitor markers (SALL4), albeit retaining biphenotypical 
markers.  
In summary, our study provides a comprehensive molecular characterization of mixed 
HCC-CCA. First, from the molecular standpoint both the stem-cell and classical types 
retain biliary and HCC components, and thus fit within the HCC-iCCA definition. 
Conversely, our data supports defining CLC as a distinct biliary-derived molecular entity 
with no HCC traits. These results provide the rationale for re-defining the current 
pathological classification [2], and for establishing more precise therapeutic approaches.  
23 
 
ACKNOWLEDGMENTS 
We would like to thank the Biorepository Tissue Bank at the Icahn School of Medicine at 
Mount Sinai for providing the FF-OCT samples, and Dr. Mireia Castillo-Martin and Yayoi 
Kinoshita for their generous help in reviewing and processing the samples. We would also 
like to thank Dr. Yujin Hoshida for his support with gene expression data normalization 
and advice. This work was supported in part through the computational resources and 
staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount 
Sinai. 
  
24 
 
REFERENCES 
[1] Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. 
Hepatocellular carcinoma. Nat Rev Dis Prim 2016;2:16018.  
[2] Theise ND, Nakashima O, Park YN, Nakanuma Y. Combined hepatocellular-
cholangiocarcinoma. WHO Classification of Tumours of the Digestive System, 4th, 
BosmanFT, Carneiro F, Hruban RH, Theise ND. (Eds), IARC, Lyons 2010. p. 225–7. 
 [3] Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, et al. Combined 
hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic 
factors. Cancer 2002;94:2040–6. 
[4] Wachtel MS, Zhang Y, Xu T, Chiriva-Internati M, Frezza EE. Combined 
hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol 
2008;1:43–7. 
[5] Sempoux C, Fan C, Singh P, Obeidat K, Roayaie S, Schwartz M, et al. 
Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking 
ductular reaction. Semin Liver Dis 2011;31:104–10. 
[6] Lee J-H, Chung GE, Yu SJ, Hwang SY, Kim JS, Kim HY, et al. Long-term prognosis 
of combined hepatocellular and cholangiocarcinoma after curative resection 
comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin 
Gastroenterol 2011;45:69–75. 
[7] Yin X, Zhang B-H, Qiu S-J, Ren Z-G, Zhou J, Chen X-H, et al. Combined 
hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment 
modalities, and prognosis. Ann Surg Oncol 2012;19:2869–76. 
[8] Lee W-S, Lee K-W, Heo J-S, Kim S-J, Choi S-H, Kim Y-I, et al. Comparison of 
combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma 
and intrahepatic cholangiocarcinoma. Surg Today 2006;36:892–7.  
[9] Sasaki M, Sato H, Kakuda Y, Sato Y, Choi JH, Nakanuma Y. Clinicopathological 
significance of “subtypes with stem-cell feature” in combined hepatocellular-
cholangiocarcinoma. Liver Int 2015;35:1024–35. 
[10] Ikeda H, Harada K, Sato Y, Sasaki M, Yoneda N, Kitamura S, et al. 
Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with 
stem cell subtype components with reference to the expression of putative stem cell 
25 
 
markers. Am J Clin Pathol 2013;140:329–40. 
[11] Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, et al. 
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic 
progenitor cell origin. Hepatology 2008;47:1544–56. 
[12] Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, et al. Transcriptomic 
profiling reveals hepatic stem-like gene signatures and interplay of mir-200c and 
EMT in intrahepatic cholangiocarcinoma. Hepatology 2012;56:1792–803. 
[13] Coulouarn C, Cavard C, Rubbia-Brandt L, Audebourg A, Dumont F, Jacques S, et 
al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and 
activation of Wnt and TGFβ signaling pathways. Carcinogenesis 2012;33:1791–6. 
[14] Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K, et al. Whole-
genome mutational landscape of liver cancers displaying biliary phenotype reveals 
hepatitis impact and molecular diversity. Nat Commun 2015;6:6120. 
[15] Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, et al. Identification of a 
cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer 
Res 2010;70:3034–41. 
[16] Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanché H, Franco D, 
et al. Clinical and molecular analysis of combined hepatocellular-
cholangiocarcinomas. J Hepatol 2004;41:292–8. 
[17] Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining 
clinical, pathology, and gene expression data to predict recurrence of hepatocellular 
carcinoma. Gastroenterology 2011;140:1501–12.e2. 
[18] Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative 
Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That 
Have Different Outcomes. Gastroenterology 2013;144:829–40. 
[19] Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. 
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary 
cancer. Nature 2014;513:110–4. 
[20] Hoshida Y, Nijman SMB, Kobayashi M, Chan JA, Brunet J-PP, Chiang DY, et al. 
Integrative transcriptome analysis reveals common molecular subclasses of human 
hepatocellular carcinoma. Cancer Res 2009;69:7385–92. 
26 
 
[21] Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene 
expression signature in mouse hepatocytes predicts clinical outcome in human 
cancer. Hepatology 2008;47:2059–67. 
[22] Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. 
Spatiotemporal dynamics of intratumoral immune cells reveal the immune 
landscape in human cancer. Immunity 2013;39:782–95. 
[23] Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-
fetoprotein expression defines novel prognostic subtypes of hepatocellular 
carcinoma. Cancer Res 2008;68:1451–61. 
[24] Chiang DYY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. Focal 
gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer 
Res 2008;68:6779–88. 
[25] Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, et al. 
Transcriptome classification of HCC is related to gene alterations and to new 
therapeutic targets. Hepatology 2007;45:42–52. 
[26] Lee J-S, Chu I-S, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and 
prediction of survival in hepatocellular carcinoma by gene expression profiling. 
Hepatology 2004;40:667–76. 
[27] Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DYY, Solé M, et al. IGF 
activation in a molecular subclass of hepatocellular carcinoma and pre-clinical 
efficacy of IGF-1R blockage. J Hepatol 2010;52:550–9. 
[28] Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, et al. Notch 
signaling is activated in human hepatocellular carcinoma and induces tumor 
formation in mice. Gastroenterology 2012;143:1660–9 e7. 
[29] Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic 
and genetic characterization of cholangiocarcinoma identifies therapeutic targets for 
tyrosine kinase inhibitors. Gastroenterology 2012;142:1021–31 e15.  
[30] Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, et al. Massive parallel 
sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in 
intrahepatic cholangiocarcinoma. Nat Commun 2015;6:6087.  
[31] Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome 
27 
 
sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 2012;44:690–
3. 
[32] Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, et al. 
Exome sequencing of hepatocellular carcinomas identifies new mutational 
signatures and potential therapeutic targets. Nat Genet 2015;47:505–11.  
[33] Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, et al. Trans-
ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 
2014;46:1267–73. 
[34] Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. 
Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153–8.  
[35] Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013;153:17–37.  
[36] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. 
Cancer genome landscapes. Science 2013;339:1546–58.  
[37] Hoshida Y, Brunet J-P, Tamayo P, Golub TR, Mesirov JP. Subclass mapping: 
identifying common subtypes in independent disease data sets. PLoS One 
2007;2:e1195. 
[38] Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenbergen W, Verslype C, 
et al. Histological diversity in cholangiocellular carcinoma reflects the different 
cholangiocyte phenotypes. Hepatology 2012;55:1876–88. 
[39] Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, et al. 
Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma 
according to the latest WHO classification. Am J Surg Pathol 2013;37:496–505. 
[40] Massagué J. TGFbeta in Cancer. Cell 2008;134:215–30.  
[41] Wu K, Ding J, Chen C, Sun W, Ning B-F, Wen W, et al. Hepatic transforming growth 
factor beta gives rise to tumor-initiating cells and promotes liver cancer 
development. Hepatology 2012;56:2255–67. 
[42] Karkampouna S, Ten Dijke P, Dooley S, Julio MK. TGFβ signaling in liver 
regeneration. Curr Pharm Des 2012;18:4103–13. 
[43] Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, et al. 
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-
28 
 
derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation 
antigen-positive myeloid cell infiltration in mice. Hepatology 2014;59:1435–47.  
[44] Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, et al. Chemokine-driven lymphocyte 
infiltration: an early intratumoural event determining long-term survival in resectable 
hepatocellular carcinoma. Gut 2012;61:427–38.  
[45] Gao Q, Qiu S-J, Fan J, Zhou J, Wang X-Y, Xiao Y-S, et al. Intratumoral balance of 
regulatory and cytotoxic T cells is associated with prognosis of hepatocellular 
carcinoma after resection. J Clin Oncol 2007;25:2586–93.  
[46] Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et 
al. Type, density, and location of immune cells within human colorectal tumors 
predict clinical outcome. Science 2006;313:1960–4.  
[47] Yong KJ, Gao C, Lim JSJ, Yan B, Yang H, Dimitrov T, et al. Oncofetal gene SALL4 
in aggressive hepatocellular carcinoma. N Engl J Med 2013;368:2266–76.  
[48] Fujii H, Zhu XG, Matsumoto T, Inagaki M, Tokusashi Y, Miyokawa N, et al. Genetic 
classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol 
2000;31:1011–7. 
[49] Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Molecular Pathogenesis and 
Targeted Therapies for Intrahepatic Cholangiocarcinoma. Clin Cancer Res 
2016;22:291–300. 
  
29 
 
TABLES 
 
Table 1: Clinico-pathological characteristics of mixed HCC-CCA cohort according to mixed 
molecular subclass. 
Variable Total  CLC Stem-cell Classical p-value 
Patients, n 18 6 8 4   
Gender, n         0.376 
  Male 14 5 7 2   
  Female 4 1 1 2   
Age, years         0.976 
  Median (range) 55 (15-82) 56 (15-82) 57 (33-71) 54 (49-66)   
Etiology, n         0.599 
  Hepatitis C 8 4 3 1   
  Hepatitis B 7 1 4 2   
  PSC 1 0 0 1   
  Others 1 1 0 0   
  None 1 0 1 0   
Cirrhosis, n         0.235 
  Absent 8 1 5 2   
  Present 10 5 3 2   
Tumor size, cm         0.225 
  Median (range) 3.2 (0.5-13.5) 1.5 (0.5-8) 3.1 (1.0-13.5) 6.3 (2.5-9)   
Satellites, n         0.235 
  Absent 10 5 3 2   
  Present 8 1 5 2   
Microvascular invasion, n         0.559 
  Absent 3 2 1 0   
  Present 15 4 7 4   
Macrovascular invasion, n         0.275 
  Absent 15 4 8 3   
  Present 3 2 0 1   
AFP, ng/mL
1
         0.953 
  Median (range) 19 (1-1573) 33 (1-1573) 18 (4-842) 114 (5-223)   
CA 19-9, UI/mL
1
         0.461 
  Median (range) 186 (8-945) 124 (8-318) 244 (8-945) 440 (20-472)   
Albumin, g/dL
2
         0.049 
  Median (range) 4.1 (3.3-4.8) 4.0 (3.7-4.3) 4.5 (3.3-4.8) 4.0 (3.4-4.1)   
Bilirrubin, mg/dL
2
         0.104 
 
Median (range) 0.6 (0.3-3.4) 0.9 (0.6-1.3) 0.5 (0.3-3.4) 0.5 (0.4-0.6)   
CLC: cholangiolocellular carcinoma. Stem cell subclass includes the histological stem cell feature typical and 
intermediate subtypes. 
1
 Not available in 5 patients 
    2
 Not available in 1 patient 
    
p-value corresponds to statistical analysis of the 3 molecular subclasses. Fisher Exact Probability Test was 
used for categorical variables and The Kruskal-Wallis Test for the continuous factors. 
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FIGURE LEGENDS 
Figure 1: Molecular classes of mixed HCC-CCA and correlation with 
histopathological features. A) Non-negative matrix factorization–based clustering 
analysis of 22 tumor samples from 18 patients with mixed HCC-CCA. B) Heat-map 
representing expression of specific cell lineage gene markers (upper panel) and 
immunostainig profiling data (lower panel) of HCC-CCA tumors. The iCCA and HCC 
components of classical subclass were analyzed separately.  
Figure 2: Integrative genomic analysis of HCC-CCA with HCC and iCCA. A) 
Unsupervised hierarchal clustering analysis was performed on merged gene expression 
profile cohorts of HCC-CCA (6 CLCs and 8 stem-cell subclass), HCC (n=164) and iCCA 
(n=149). Integration of the datasets was based on the Z-score transformation of the 
differentially expressed gene in each independent cohort. Nearest prediction method was 
used for the association with liver cancer derived gene signatures. B) Schematic 
representation of overlapping molecular profile and genomic proximity of CLC and stem-
cell subclass mixed tumors with iCCA and HCC, respectively, based on unsupervised 
clustering analysis. Statistically significant association was calculated by Fisher Exact 
Probability Test (p<0.05).  
Figure 3: Immunostaining profile of mixed HCC-CCA subclasses. Representative 
morphological and positive immunohistochemical staining features observed for each 
mixed HCC-CCA subclass.  
Figure 4: Broad chromosomal alterations detected in mixed HCC-CCA subclasses. 
Chromosome arms are displayed in descending order along the vertical axis. Detected 
broad chromosomal gains, losses, and copy neutral loss of heterozygosity (CN-LOH) per 
tumor sample have been highlighted. The iCCA and HCC components of each classical 
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case were analyzed separately. Bars indicate the total number of broad chromosomal 
gains and losses. CLC showed higher chromosomal stability in comparison to other mixed 
HCC-CCAs (p<0.01, two-sided T-test). 
Figure 5: Whole-genome gene expression analysis of different mixed HCC-CCA 
subclasses. A) Heat-map representing prediction of liver cancer derived molecular 
classification and gene signatures (upper panel), immune-related gene signatures for cell 
type and activated signaling (lower panel). B) Network analysis of deregulated genes in 
CLC showed TGF-β signaling as one of the main activated signaling nodes. C) Network 
analysis of deregulated genes in SALL4 stem-cell subclass showed activation of IGF2 
signaling and hepatic specification of progenitor cells. In the network analyses, a node 
symbolizes a gene or gene product, and direct and indirect interactions are indicated by 
solid lines and dotted lines, respectively. Statically significant associated features in CLC 
are highlighted with (*) and in stem-cell subclass with (¥) using Fisher Exact Probability 
Test for categorical variables and two-sided T-test for continuous variables. *p<0.05, 
**p<0.01, ***p<0.001. The iCCA and HCC components of each classical case were 
analyzed separately. 
Figure 6: Mutational profile of mixed HCC-CCA. A) Histogram of the number of 
mutations in each primary tumor sample (upper panel) and pie chart representation of the 
percentage of non-synonymous somatic mutations for CLC and stem-cell subclasses 
(lower panel). B) Heat-map representing the individual mutation in known cancer driver 
genes identified by exome-sequencing. C) Heat-map representing the validation of 
exome-sequencing results and screening of the most prevalent oncogenic mutations 
reported in HCC and iCCA in the study cohort. Overlapping cases from which fresh-frozen 
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and FFPE samples were analyzed separately by exome-sequencing and PCR validation 
are highlighted with an asterisk. 
Figure 7: Summary of molecular characterization of mixed HCC-CCAs and CLC 
tumors as distinct entities. CLC only share biliary-derived features, as opposed to HCC-
iCCA tumors. Specific cell lineage markers, liver cancer derived gene signatures, pathway 
signaling, chromosomal stability and driver mutations are depicted for each entity.  
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